Pritelivir
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Pritelivir
- DrugBank Accession Number
- DB11844
- Background
Pritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 402.49
Monoisotopic: 402.082032804 - Chemical Formula
- C18H18N4O3S2
- Synonyms
- Pritelivir
- External IDs
- AIC-316
- AIC316
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAdenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Pritelivir. Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Pritelivir. Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pritelivir. Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pritelivir. Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Pritelivir. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Phenylpyridines
- Direct Parent
- Phenylpyridines
- Alternative Parents
- Phenylacetamides / 2,4,5-trisubstituted thiazoles / Organosulfonamides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides show 2 more
- Substituents
- 2,4,5-trisubstituted 1,3-thiazole / 2-phenylpyridine / Aminosulfonyl compound / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 07HQ1TJ4JE
- CAS number
- 348086-71-5
- InChI Key
- IVZKZONQVYTCKC-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
- IUPAC Name
- N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide
- SMILES
- CN(C(=O)CC1=CC=C(C=C1)C1=CC=CC=N1)C1=NC(C)=C(S1)S(N)(=O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 491941
- PubChem Substance
- 347828188
- ChemSpider
- 430613
- BindingDB
- 50237366
- ChEMBL
- CHEMBL4069597
- ZINC
- ZINC000003955689
- Wikipedia
- Pritelivir
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Available Not Available HSV 1 somestatus stop reason just information to hide 3 Recruiting Treatment Herpes Simplex Infections 1 somestatus stop reason just information to hide 2 Completed Prevention HSV-2 / HSV-2 Infection 1 somestatus stop reason just information to hide 2 Completed Treatment Herpes Labialis 1 somestatus stop reason just information to hide 2 Terminated Prevention Genital Herpes 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0115 mg/mL ALOGPS logP 2.37 ALOGPS logP 1.97 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 8.58 Chemaxon pKa (Strongest Basic) 4.42 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 106.25 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 101.96 m3·mol-1 Chemaxon Polarizability 41.27 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0pb9-0090500000-4e918e226f82f34b6031 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0pdi-0491400000-8f1e957b87dc9ec6467e Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0010900000-378ceed90c78f0eef585 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9010000000-2867667bd98beb24c63d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-016r-0920000000-13d5332d52f774e465bf Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9601000000-f3e01f756d2c834baf5e Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 210.8699913 predictedDarkChem Lite v0.1.0 [M-H]- 185.10674 predictedDeepCCS 1.0 (2019) [M+H]+ 211.5638913 predictedDarkChem Lite v0.1.0 [M+H]+ 187.46474 predictedDeepCCS 1.0 (2019) [M+Na]+ 210.6746913 predictedDarkChem Lite v0.1.0 [M+Na]+ 193.9013 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:53 / Updated at February 21, 2021 18:53